The dual peroxisome proliferator-activated receptor α/γ agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin

Metabolism: Clinical and Experimental

Volumn 56, Issue 9, 2007, Pages 1285-1292

  Tonstad, Serena ^a   Retterstøl, Kjetil ^b   Ose, Leiv ^b   Öhman, K Peter ^c   Lindberg, Magnus B ^d   Svensson, Maria ^d  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CREATININE; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; TESAGLITAZAR; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DEPRESSION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FATALITY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34547774295     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.05.003     Document Type: Article

References (28)

1. Betteridge D.J. Diabetic dyslipidaemia. Diabetes Obes Metab 2 Suppl 1 (2000) S31-S36
2. Sniderman A.D., Scantlebury T., and Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135 (2001) 447-459
3. Taskinen M.R. Diabetic dyslipidemia. Atheroscler Suppl 3 (2002) 47-51
4. Nesto R.W. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 5 (2005) 379-387
5. Austin M.A., Breslow J.L., Hennekens C.H., et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
6. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
7. Austin M.A. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol 83 (1999) 13F-16F
8. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 Suppl 1 (2004) S43-S50
9. Staels B., Dallongeville J., Auwerx J., et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
10. Fagerberg B., Edwards S., Halmos T., et al. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48 (2005) 1716-1725
11. Goldstein B.J., Rosenstock J., Anzalone D., et al. Effect of tesaglitazar, a dual PPARa/g agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr Med Res Opin 22 (2006) 2575-2590
12. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
13. Ferrannini E., Gastaldelli A., Matsuda M., et al. Influence of ethnicity and familial diabetes on glucose tolerance and insulin action: a physiological analysis. J Clin Endocrinol Metab 88 (2003) 3251-3257
14. Rosenberg D.E., Jabbour S.A., and Goldstein B.J. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. Diabetes Obes Metab 7 (2005) 642-653
15. Murdock D.K., Jansen D., Juza R.M., et al. Benefit of adding pioglitazone to statin therapy in non-diabetic patients with the metabolic syndrome. WMJ 105 (2006) 22-25
16. Berhanu P., Kipnes M.S., Khan M.A., et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 3 (2006) 39-44
17. Lewin A.J., Kipnes M.S., Meneghini L.F., et al. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 26 (2004) 379-389
18. Waugh J., Keating G.M., Plosker G.L., et al. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 66 (2006) 85-109
19. Anonymous. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
20. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 24 (2004) e149-e161
21. P. Thalen, S. Jacinto, T. Hultstrand, et al. AZ 242, a novel PPARα/γ agonist, ameliorates glucose and lipid intolerance in obese Zucker rats following an oral combined glucose and lipid load. P-489 American Diabetes Association, PA, USA, June 22-26, 2001.
22. Shachter N.S. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 12 (2001) 297-304
23. Jong M.C., Hofker M.H., and Havekes L.M. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19 (1999) 472-484
24. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
25. Berneis K.K., and Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43 (2002) 1363-1379
26. Okada M., Matsuto T., Miida T., et al. Lipid analyses for the management of vascular diseases. J Atheroscler Thromb 11 (2004) 190-199
27. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
28. Broeders N., Knoop C., Antoine M., et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?. Nephrol Dial Transplant 15 (2000) 1993-1999